<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001992</url>
  </required_header>
  <id_info>
    <org_study_id>075A</org_study_id>
    <secondary_id>V0200g</secondary_id>
    <nct_id>NCT00001992</nct_id>
  </id_info>
  <brief_title>A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers</brief_title>
  <official_title>A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive&#xD;
      adult patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rgp120/HIV-1IIIB</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals.&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent form, which must be&#xD;
             obtained prior to study entry.&#xD;
&#xD;
          -  Be available for 24 weeks so that follow up may be completed.&#xD;
&#xD;
          -  Qualify for care as Department of Defense health care beneficiary.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic&#xD;
             or autoimmune disease, other than HIV-1 infection, and in less than average general&#xD;
             health as determined by a medical history, physical examination, and the required&#xD;
             laboratory test results.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Corticosteroids or other known immunosuppressive drugs.&#xD;
&#xD;
          -  Any experimental agents.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic&#xD;
             or autoimmune disease, other than HIV-1 infection, and in less than average general&#xD;
             health as determined by a medical history, physical examination, and the required&#xD;
             laboratory test results.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Zidovudine or other anti-retroviral agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

